ConductScience.org, home

Comparison · NCT00114972-7a85a210

CABG vs PCI With DES: Primary Clinical Endpoint of 12-Month Binary MACCE.

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. CABG vs PCI With DES: Primary Clinical Endpoint of 12-Month Binary MACCE. Trial comparisons, record NCT00114972-7a85a210. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00114972-7a85a210

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.1240.1030.148wilson
Risk in group 20.1780.1550.205wilson
Risk difference, group 1 minus group 2-0.0548-0.0883-0.0211newcombe hybrid score
Risk ratio, group 1 over group 20.6930.5520.87log
Odds ratio, group 1 over group 20.650.4980.848log
Number needed to treat, for one fewer participant with the outcome on CABG than on PCI With DES18.311.347.4from the risk difference interval

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1CABGCoronary Artery By-pass Graft (CABG)105849OG000
Group 2PCI With DESPercutaneous coronary intervention (PCI) using TAXUS Express Drug Eluting Stent (DES)159891OG001

Outcome

Type
PRIMARY
Title
Primary Clinical Endpoint of 12-Month Binary MACCE.
Description
Number of participants at primary clinical endpoint of 12-Month binary MACCE. MACCE is defined as: all cause death, cerebrovascular event (stroke), cocumented myocardial infarction, repeat revascularization (PCI and/or CABG).
Time frame
12 months post enrollment
Population
ITT analysis. Number of participants analyzed equals number of subjects who completed Overall Study, as listed in Participant Flow.

Source ClinicalTrials.gov

Trial

Title
SYNTAX Study: TAXUS Drug-Eluting Stent Versus Coronary Artery Bypass Surgery for the Treatment of Narrowed Arteries
NCT number
NCT00114972
Phases
PHASE3
Conditions
Coronary Artery Disease
Interventions
Polymer-based Paclitaxel-Eluting TAXUS Express2-SR Stent, Coronary Artery Bypass Surgery
Lead sponsor
Boston Scientific Corporation
Results first posted
2010-06-23

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT00114972-7a85a210